Recent progress of graphene oxide as a potential vaccine carrier and adjuvant (June 2020 review paper)
excerpt:
However, the studies of Functionalized Graphene Oxides (FGOs) for vaccine application are in the early stage, and it still faces problems and challenges on the way to clinical application. There is no study yet to confirm the biosafety of FGOs in the human body. Clinical trials and more in vivo preclinical studies are needed to provide information on FGOs’ biocompatibility, biodegradation, biodistribution, and toxicity. Regarding the studies to date, most of them have only examined the single role of FGOs as adjuvants or carriers. In addition, researchers have studied the ability of FGOs in loading and delivering only a few types of antigens and adjuvants, such as OVA and CPG ODNs.
Independent Researchers find that Pfizer COVID vax contains 99.1% Graphene Oxide
VIDEO
https://ncrenegade.com/breaking-discovery-the-actual-contents-inside-pfizer-vials-exposed/